OBINUTUZUMAB, RITUXIMAB
APHP 211038
Phase 3 small_molecule active
Quick answer
OBINUTUZUMAB, RITUXIMAB for Idiopathic nephrotic syndrome (INS) is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Idiopathic nephrotic syndrome (INS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active